SCHEMBL25369870

SCHEMBL25369870

CC(C)Oc1ccccc1NC(=O)c1csc(C(=O)Nc2cccc(NS(C)(=O)=O)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MRGPRX1 Q96LB2 1/20 0.46
▸ KCNK3 O14649 2/20 0.45
▸ KCNK9 Q9NPC2 2/20 0.45
▸ RXFP1 Q9HBX9 3/20 0.44
▸ HTR2A P28223 1/20 0.44
▸ TSPO P30536 1/20 0.44
▸ GPR183 P32249 1/20 0.44
▸ APLNR P35414 1/20 0.44
▸ DHX9 Q08211 1/20 0.44
▸ HPGD P15428 3/20 0.43
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ MAPT P10636 2/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ MAPK10 P53779 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC8 Q9BY41 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30543904 0.89 DHX9 (0.50) RXFP1DHX9HPGDMEN1KMT2A
SCHEMBL25368623 0.89 DHX9 (0.50) RXFP1DHX9HPGDMEN1KMT2A
SCHEMBL30543909 0.88 ATM (0.49) KCNK3KCNK9RXFP1DHX9HPGD
SCHEMBL25367764 0.88 ATM (0.49) KCNK3KCNK9RXFP1DHX9HPGD
SCHEMBL25368128 0.85 EPHX2 (0.48) DHX9HPGDMEN1KMT2AMAPT
SCHEMBL30543946 0.84 DHX9 (0.53) KCNK3KCNK9DHX9HPGDMEN1
SCHEMBL25368280 0.84 DHX9 (0.53) KCNK3KCNK9DHX9HPGDMEN1
SCHEMBL30544050 0.81 ALDH1A1 (0.53) HPGDMEN1KMT2AMAPTLMNA
SCHEMBL25366920 0.81 ALDH1A1 (0.53) HPGDMEN1KMT2AMAPTLMNA
SCHEMBL25368236 0.81 BCHE (0.46) KCNK3KCNK9DHX9HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US claimed
EP-4479380-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Accent Therapeutics, Inc. (US) 2024-12-25 — — EP claimed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO claimed
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US disclosed
EP-4479380-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Accent Therapeutics, Inc. (US) 2024-12-25 — — EP disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B MRGPRX1 2831/4885KCNK3 3925/4885KCNK9 2279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback